The action and toxicity of taxanes (Q46416244)

22 December 2017

review article

1 reference

title

The action and toxicity of taxanes (English)

1 reference

22 December 2017

1

Hans-Peter Lipp

1 reference

22 December 2017

2

Carsten Bokemeyer

1 reference

22 December 2017

language of work or name

German

0 references

publication date

1 January 2005

1 reference

22 December 2017

Pharmazie in unserer Zeit

published in

1 reference

22 December 2017

volume

34

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

128-137

1 reference

22 December 2017

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Effectiveness of cold cap in the prevention of docetaxel-induced alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Taxane-induced nail changes: incidence, clinical presentation and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Paclitaxel formulation as a cause of ethanol intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Use of gabapentin to treat taxane-induced myalgias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Docetaxel with epirubicin--investigations on cardiac safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPAUZ.200400113

21 January 2018

Identifiers

DOI

10.1002/PAUZ.200400113

1 reference

22 December 2017

1 reference

22 December 2017